| DOMAIN Study: A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region. |
Ongoing |
Acalabrutinib |
4 |
D8220R0008 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam) |
| Real-World Effectiveness and Safety Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Sacituzumab Govitecan in Second Line and Beyond in Kingdom of Saudi Arabia. |
Ongoing |
Sacituzumab Govitecan |
4 |
GS-AE-979 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis. |
Ongoing |
Frexalimab (SAR441344) |
3 |
EFC17504 |
King Saud University Medical City (Riyadh) |
| A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. |
Ongoing |
SAR445229 (Amlitelimab) |
3 |
LTS17367 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease (EASi-PROTKT™) |
Ongoing |
Vicadrostat (BI 690517) / Empagliflozin |
3 |
1378-0041 |
Imam Abdulrahman University Hospital (Dammam) , King Abdulaziz University Hospital (Jeddah) , King Faisal Specialist Hospital and Research Center (Riyadh) , King Saud University Medical City (Riyadh) |
| A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents |
Ongoing |
Luspatercept |
2 |
CA056015 |
King Khalid University Hospital (Riyadh) |
| A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2) |
Ongoing |
Patiromer |
2 |
RLY5016-208p |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) |
Ongoing |
Dostarlimab (GSK4057190) |
3 |
221530 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Povetacicept In Adults With Immunoglobulin A Nephropathy (Rainier) |
Ongoing |
Povetacicept |
3 |
AIS-D08 |
King Saud University Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone with Background Dapagliflozin in Subjects with Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM) |
Ongoing |
Apabetalone |
2 |
RVX222-CS-025 |
King Abdulaziz Medical City NG (Al-Ahsa), King Abdulaziz Medical City NG (Riyadh) |
